Holder evidence
50
SEC ownership of RECURSION PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001601830.
Lead holder
ARK Investment Management LLC
13D/G signal
ARK Investment Management LLC
Latest evidence
15 May 2026
- CIK
- 0001601830
- Symbol
- RXRX on Nasdaq
- Location
- Salt Lake City, UT
- SEC evidence mix
- 13D/G, 13F, and 3/4/5
- Lead holder
- ARK Investment Management LLC
- Latest large-stake holder
- ARK Investment Management LLC
- Latest evidence date
- 15 May 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of RECURSION PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
ARK Investment Management...
13D/G signal
ARK Investment Management...
Evidence rows
50
Latest as of
15 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.2%
13D/G row: ARK Investment Management LLC
Showing 1-8 of 50 holder rows.
Rank 1 holder
ARK Investment Management LLC
13D/G
13F
- Ownership
- 7.2%
- Position
- $152.63M
Rank 2 holder
BlackRock, Inc.
13F
13D/G
- Ownership
- 7.2%
- Position
- $132.6M
Rank 3 holder
STATE STREET CORP
13F
13D/G
- Ownership
- 5.5%
- Position
- $87.47M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARK Investment Management LLC |
13D/G
13F
Company
|
7.2%
|
$152,625,941
37,316,856 shares
|
+$20,329,177 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.2%
from 13D/G
|
$132,600,379
43,192,306 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5.5%
from 13D/G
|
$87,466,259
28,490,638 shares
|
— | 31 Mar 2026 |
| BAILLIE GIFFORD & CO |
13D/G
13F
Company
|
4.6%
|
$97,239,635
23,774,972 shares
|
$0 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
2%
|
$44,187,549
7,725,096 shares
|
$0 | 31 Dec 2024 |
| David Hallett |
3/4/5
Chief Scientific Officer
|
0.2%
|
$3,286,416
1,070,494 shares
|
— | 15 May 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
4.3%
|
$69,870,437
22,759,100 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
4.2%
|
$68,290,268
22,244,387 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$12,551,893.
Buys
$0
Insiders: 0
Sells
$12,551,893
Insiders: 4
Net
-$12,551,893
Shares: -2,760,240
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 2,760,240
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 466,254 | $0 | $1,564,830 | -$1,564,830 |
| 3-6 | 0 | 1,059,212 | $0 | $4,541,125 | -$4,541,125 |
| 6-9 | 0 | 480,000 | $0 | $2,495,800 | -$2,495,800 |
| 9-12 | 0 | 754,774 | $0 | $3,950,137 | -$3,950,137 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to RECURSION PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Lead holder
Lux Ventures IV, L.P.
Net 12M change
-$12,551,893
Latest report
22 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lux Ventures IV, L.P. | Former 10% Owner | $137,710,376 | Mixed | 07 Dec 2021 | ||
| Mubadala Investment Co PJSC | 10%+ Owner | $137,333,970 | Mixed | 02 Mar 2023 | ||
| Zachary Bogue | Director, 10%+ Owner | $39,514,048 | Mixed | 03 Jul 2023 | ||
| Blake Borgeson | Director | $21,823,517 | -$3,631,400 | -14% | Filing P/S | 05 May 2026 |
| MIC Capital Partners (Public) Parallel Cayman, LP | 10%+ Owner | $14,688,335 | Mixed | 01 Nov 2021 | ||
| Dean Y. Li | Director | $13,187,001 | Mixed | 01 Apr 2026 | ||
| Michael Secora | Chief Financial Officer | $9,186,510 | Mixed | 15 Nov 2024 | ||
| Najat Khan | CEO and President, Director | $6,752,108 | -$845,425 | -11% | Median | 15 May 2026 |
| Ben R. Taylor | Chief Financial Officer | $3,399,325 | -$157,704 | -4.4% | Median | 15 May 2026 |
| David Hallett | Chief Scientific Officer | $3,286,416 | Median | 15 May 2026 | ||
| Tina Marriott | President and COO | $3,129,811 | Mixed | 15 Nov 2024 | ||
| Christopher Gibson | Director | $2,721,903 | -$7,917,364 | -74% | Filing P/S | 22 May 2026 |
| Shafique Virani | Chief Business Officer | $1,446,192 | Mixed | 16 Jan 2024 | ||
| David J. Mauro | Chief Medical Officer | $1,392,024 | Mixed | 15 Nov 2024 | ||
| Ramona Doyle | Chief Medical Officer | $1,280,811 | Mixed | 16 May 2022 | ||
| Zavain Dar | Director | $602,174 | Mixed | 01 Apr 2026 | ||
| Franziska Michor | Director | $565,385 | Mixed | 18 Jun 2025 | ||
| CHAVEZ R. MARTIN | Director | $529,780 | Mixed | 01 Apr 2024 | ||
| Terry-Ann Burrell | Director | $514,098 | Mixed | 01 Jul 2024 | ||
| Robert Hershberg | Director | $328,107 | Mixed | 18 Jun 2025 |
Recent insider transactions for RECURSION PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.33% | $123,200 | $3.08 | -40,000 | 883,735 | 22 May 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.53% | 40,000 | 923,735 | 22 May 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.92% | -40,000 | 4,303,334 | 22 May 2026 | Direct | ||
| David Hallett | RXRX | Class A Common Stock | Tax liability | -2.43% | -26,657 | 1,070,494 | 15 May 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Tax liability | -2.77% | -62,701 | 2,199,384 | 15 May 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Tax liability | -2.52% | -22,821 | 883,735 | 15 May 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -2.21% | -25,018 | 1,107,272 | 15 May 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Gift | -2.16% | -20,000 | 906,556 | 07 May 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.14% | $134,800 | $3.37 | -40,000 | 926,556 | 07 May 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 6.62% | 60,000 | 966,556 | 07 May 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -1.36% | -60,000 | 4,343,334 | 07 May 2026 | Direct | ||
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -0.48% | $105,600 | $3.52 | -30,000 | 6,199,863 | 05 May 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $144,400 | $3.61 | -40,000 | 906,556 | 22 Apr 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 22 Apr 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.9% | -40,000 | 4,403,334 | 22 Apr 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $124,000 | $3.10 | -40,000 | 906,556 | 07 Apr 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 07 Apr 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.89% | -40,000 | 4,443,334 | 07 Apr 2026 | Direct | ||
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -0.48% | $93,000 | $3.10 | -30,000 | 6,229,863 | 07 Apr 2026 | Direct |
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -4.07% | -48,028 | 1,132,290 | 06 Apr 2026 | Direct | ||
| Zavain Dar | RXRX | Class A Common Stock | Award | 3.44% | 4,902 | 147,231 | 01 Apr 2026 | Direct | ||
| Dean Y. Li | RXRX | Class A Common Stock | Award | 0.26% | 3,268 | 1,244,177 | 01 Apr 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $130,000 | $3.25 | -40,000 | 906,556 | 23 Mar 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 23 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.88% | -40,000 | 4,483,334 | 23 Mar 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Sale | -0.67% | $26,971 | $3.39 | -7,956 | 1,180,318 | 17 Mar 2026 | Direct |
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -0.59% | -7,075 | 1,188,274 | 16 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Gift | -2.16% | -20,000 | 906,556 | 09 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 2.21% | 20,000 | 926,556 | 09 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.44% | -20,000 | 4,523,334 | 09 Mar 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Sale | -1.24% | $94,660 | $3.35 | -28,298 | 2,262,085 | 09 Mar 2026 | Direct |
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -2.64% | $588,200 | $3.46 | -170,000 | 6,259,863 | 03 Mar 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $138,400 | $3.46 | -40,000 | 906,556 | 19 Feb 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 19 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.87% | -40,000 | 4,543,334 | 19 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Sale | -1.11% | $41,352 | $3.08 | -13,426 | 1,195,349 | 18 Feb 2026 | Direct |
| David Hallett | RXRX | Class A Common Stock | Tax liability | -1.07% | -11,908 | 1,097,151 | 17 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Tax liability | -2.92% | -27,265 | 906,556 | 17 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -0.98% | -11,908 | 1,208,775 | 17 Feb 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Tax liability | -0.62% | -14,280 | 2,290,383 | 17 Feb 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Tax liability | -0.45% | -10,364 | 2,304,663 | 06 Feb 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Award | 278.8% | 1,703,892 | 2,315,027 | 06 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -0.93% | -11,400 | 1,220,683 | 06 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Award | 61.8% | 470,533 | 1,232,083 | 06 Feb 2026 | Direct | ||
| David Hallett | RXRX | Class A Common Stock | Tax liability | -1.02% | -11,400 | 1,109,059 | 06 Feb 2026 | Direct | ||
| David Hallett | RXRX | Class A Common Stock | Award | 88.6% | 526,318 | 1,120,459 | 06 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Tax liability | -1.1% | -10,364 | 933,821 | 06 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Award | 3.32% | 30,346 | 944,185 | 06 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.19% | $164,800 | $4.12 | -40,000 | 913,839 | 04 Feb 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.38% | 40,000 | 953,839 | 04 Feb 2026 | Direct |
* indicates a reported price that failed the local validity check.